Autolus Therapeutics Plc ADR (AUTL) Stock Price, Quote & News

Latest News on AUTL

$Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)$

Apr 25, 2025, 12:06 PM EDT - 3 days ago

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Apr 23, 2025, 4:05 PM EDT - 5 days ago

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Apr 22, 2025, 7:00 AM EDT - 6 days ago

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 2, 2025, 7:00 AM EDT - 26 days ago

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 27 days ago

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Mar 20, 2025, 11:55 AM EDT - 5 weeks ago

Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript

Mar 20, 2025, 7:00 AM EDT - 5 weeks ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 6, 2025, 7:00 AM EST - 7 weeks ago

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Mar 5, 2025, 7:00 AM EST - 7 weeks ago

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Mar 4, 2025, 10:21 AM EST - 7 weeks ago

Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy

Jan 17, 2025, 7:00 AM EST - 3 months ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Dec 9, 2024, 7:30 PM EST - 4 months ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Nov 21, 2024, 12:16 AM EST - 5 months ago

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Nov 12, 2024, 2:57 PM EST - 5 months ago

Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript

$Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)$

Nov 8, 2024, 4:23 PM EST - 6 months ago

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Oct 28, 2024, 5:00 PM EDT - 6 months ago

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Sep 6, 2024, 2:12 PM EDT - 8 months ago

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Aug 10, 2024, 12:05 AM EDT - 9 months ago

Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript

Jul 26, 2024, 7:00 AM EDT - 9 months ago

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

$Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress$

Jun 14, 2024, 7:00 AM EDT - 11 months ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

May 31, 2024, 8:00 AM EDT - 11 months ago

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

May 17, 2024, 12:55 PM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript

May 17, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 14, 2024, 1:02 PM EDT - 1 year ago

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

Apr 24, 2024, 10:00 AM EDT - 1 year ago

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Announces Changes to its Board of Directors

Mar 15, 2024, 5:23 AM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Mar 12, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Feb 29, 2024, 7:00 AM EST - 1 year ago

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Feb 8, 2024, 7:00 AM EST - 1 year ago

Autolus Announces Pricing of Underwritten Offering

Feb 8, 2024, 5:45 AM EST - 1 year ago

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Feb 6, 2024, 9:52 AM EST - 1 year ago

Autolus Upgrades Leadership And Faces CAR-T Approval

Jan 23, 2024, 7:00 AM EST - 1 year ago

Autolus Therapeutics announces publication in ACS Chemical Biology

$Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)$

Jan 22, 2024, 7:00 AM EST - 1 year ago

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

Dec 18, 2023, 4:12 AM EST - 1 year ago

Autolus Therapeutics: Pivotal Trial Using Familiar Approach, Possible Approval Coming Fast

Dec 9, 2023, 8:30 PM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

$Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)$

Nov 27, 2023, 7:00 AM EST - 1 year ago

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

Nov 15, 2023, 7:00 AM EST - 1 year ago

Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

Oct 11, 2023, 7:00 AM EDT - 1 year ago

Market Cap	353.91M
Revenue (ttm)	10.12M
Net Income (ttm)	-220.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,180.43%
Debt to Equity Ratio	0.00

Volume	2,288,900
Avg Vol	1,663,910
Day's Range	N/A - N/A
Shares Out	266.09M
Stochastic %K	8%
Beta	2.06
Analysts	Strong Sell
Price Target	$10.07